| Primary |
| Hypercholesterolaemia |
21.9% |
| Hypertension |
21.2% |
| Dyslipidaemia |
8.8% |
| Myocardial Infarction |
6.1% |
| Prophylaxis |
4.9% |
| Pain |
3.8% |
| Acute Coronary Syndrome |
3.6% |
| Cerebrovascular Accident |
3.1% |
| Depression |
3.1% |
| Diabetes Mellitus |
3.1% |
| Atrial Fibrillation |
3.0% |
| Type 2 Diabetes Mellitus |
2.7% |
| Coronary Artery Disease |
2.4% |
| Cardiac Failure |
2.0% |
| Blood Cholesterol |
1.9% |
| Cardiovascular Event Prophylaxis |
1.9% |
| Thrombosis Prophylaxis |
1.9% |
| Product Used For Unknown Indication |
1.7% |
| Anxiety |
1.5% |
| Arrhythmia |
1.5% |
|
| Rhabdomyolysis |
15.1% |
| Cytolytic Hepatitis |
9.0% |
| Myalgia |
8.5% |
| Thrombocytopenia |
7.4% |
| Transaminases Increased |
7.1% |
| Weight Decreased |
6.3% |
| Vomiting |
4.7% |
| Tendonitis |
4.4% |
| Vertigo |
4.4% |
| Lung Disorder |
3.8% |
| Renal Failure |
3.8% |
| Interstitial Lung Disease |
3.6% |
| Hepatitis |
3.3% |
| Haematoma |
2.7% |
| Pancreatitis Acute |
2.7% |
| Rash |
2.7% |
| Tendon Rupture |
2.7% |
| Urticaria |
2.7% |
| Drug Rash With Eosinophilia And Systemic Symptoms |
2.5% |
| Malaise |
2.5% |
|
| Secondary |
| Drug Use For Unknown Indication |
33.3% |
| Product Used For Unknown Indication |
21.2% |
| Hypertension |
9.1% |
| Hypercholesterolaemia |
6.2% |
| Dyslipidaemia |
3.7% |
| Unevaluable Event |
3.5% |
| Type 2 Diabetes Mellitus |
2.8% |
| Myocardial Infarction |
2.4% |
| Prophylaxis |
2.2% |
| Diabetes Mellitus |
2.1% |
| Depression |
1.9% |
| Pain |
1.6% |
| Atrial Fibrillation |
1.5% |
| Ill-defined Disorder |
1.5% |
| Cardiac Failure |
1.5% |
| Gastrooesophageal Reflux Disease |
1.1% |
| Hypothyroidism |
1.1% |
| Anxiety |
1.1% |
| Acute Coronary Syndrome |
1.0% |
| Neck Pain |
0.9% |
|
| Renal Failure Acute |
11.9% |
| Rhabdomyolysis |
11.0% |
| Cytolytic Hepatitis |
9.4% |
| Thrombocytopenia |
9.1% |
| Vomiting |
7.8% |
| Interstitial Lung Disease |
5.0% |
| Toxic Skin Eruption |
4.4% |
| Hepatitis |
3.8% |
| Drug Rash With Eosinophilia And Systemic Symptoms |
3.4% |
| Haematoma |
3.4% |
| Pyrexia |
3.4% |
| Transaminases Increased |
3.4% |
| Weight Decreased |
3.4% |
| Lung Disorder |
3.1% |
| Peritoneal Haemorrhage |
3.1% |
| Myalgia |
2.8% |
| Pruritus |
2.8% |
| Rash |
2.8% |
| Renal Failure |
2.8% |
| Thrombocytopenic Purpura |
2.8% |
|
| Concomitant |
| Drug Use For Unknown Indication |
29.4% |
| Product Used For Unknown Indication |
22.4% |
| Hypertension |
11.9% |
| Hypercholesterolaemia |
3.7% |
| Type 2 Diabetes Mellitus |
3.7% |
| Atrial Fibrillation |
2.8% |
| Prophylaxis |
2.6% |
| Rheumatoid Arthritis |
2.6% |
| Diabetes Mellitus |
2.6% |
| Depression |
2.4% |
| Thrombosis Prophylaxis |
2.2% |
| Dyslipidaemia |
2.1% |
| Myocardial Infarction |
2.1% |
| Pain |
1.8% |
| Renal Transplant |
1.5% |
| Osteoporosis |
1.4% |
| Acute Coronary Syndrome |
1.4% |
| Epilepsy |
1.2% |
| Anxiety |
1.2% |
| Ill-defined Disorder |
1.1% |
|
| Renal Failure Acute |
16.4% |
| Vomiting |
12.6% |
| Renal Failure |
9.4% |
| Thrombocytopenia |
9.3% |
| Toxic Skin Eruption |
5.2% |
| Weight Decreased |
4.8% |
| Malaise |
4.1% |
| Hyponatraemia |
4.0% |
| International Normalised Ratio Increased |
3.7% |
| Somnolence |
3.7% |
| Urticaria |
3.1% |
| Weight Increased |
3.0% |
| Neutropenia |
2.9% |
| Transaminases Increased |
2.9% |
| Fall |
2.7% |
| Sepsis |
2.6% |
| Septic Shock |
2.6% |
| Purpura |
2.5% |
| Pyrexia |
2.3% |
| Shock Haemorrhagic |
2.3% |
|
| Interacting |
| Drug Use For Unknown Indication |
35.1% |
| Hypercholesterolaemia |
7.9% |
| Dyslipidaemia |
6.1% |
| Hypertension |
6.1% |
| Atrial Fibrillation |
5.3% |
| Acute Coronary Syndrome |
4.4% |
| Product Used For Unknown Indication |
4.4% |
| Asthma |
3.5% |
| Dermatomyositis |
3.5% |
| Pain |
3.5% |
| Rheumatoid Arthritis |
3.5% |
| Prophylaxis |
2.6% |
| Arterial Disorder |
1.8% |
| Arthralgia |
1.8% |
| Dementia Alzheimer's Type |
1.8% |
| Depression |
1.8% |
| Device Related Infection |
1.8% |
| Diabetes Mellitus |
1.8% |
| Hyperthyroidism |
1.8% |
| Liver Transplant |
1.8% |
|
| Rhabdomyolysis |
22.7% |
| Myalgia |
11.4% |
| International Normalised Ratio Increased |
6.8% |
| Overdose |
6.8% |
| Underdose |
6.8% |
| Vomiting |
6.8% |
| Drug Interaction |
4.5% |
| Rectal Haemorrhage |
4.5% |
| Staphylococcal Infection |
4.5% |
| Cytolytic Hepatitis |
2.3% |
| Decreased Appetite |
2.3% |
| Fall |
2.3% |
| Haematuria |
2.3% |
| Hypogammaglobulinaemia |
2.3% |
| Lung Disorder |
2.3% |
| Paraesthesia |
2.3% |
| Pleural Effusion |
2.3% |
| Prothrombin Time Ratio Decreased |
2.3% |
| Renal Failure |
2.3% |
| Right Ventricular Failure |
2.3% |
|
